During the last session, Zevra Therapeutics Inc (NASDAQ:ZVRA)’s traded shares were 1.0 million, with the beta value of the company hitting 1.95. At the end of the trading day, the stock’s price was $7.83, reflecting an intraday gain of 3.98% or $0.3. The 52-week high for the ZVRA share is $8.44, that puts it down -7.79 from that peak though still a striking 50.32% gain since the share price plummeted to a 52-week low of $3.89. The company’s market capitalization is $412.01M, and the average intraday trading volume over the past 10 days was 0.67 million shares, and the average trade volume was 829.28K shares over the past three months.
Zevra Therapeutics Inc (ZVRA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ZVRA has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zevra Therapeutics Inc (NASDAQ:ZVRA) trade information
Zevra Therapeutics Inc (ZVRA) registered a 3.98% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.98% in intraday trading to $7.83, hitting a weekly high. The stock’s 5-day price performance is 5.95%, and it has moved by 10.59% in 30 days. Based on these gigs, the overall price performance for the year is 52.63%. The short interest in Zevra Therapeutics Inc (NASDAQ:ZVRA) is 3.83 million shares and it means that shorts have 2.92 day(s) to cover.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 64.41% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $22 respectively. As a result, ZVRA is trading at a discount of -180.97% off the target high and -180.97% off the low.
Zevra Therapeutics Inc (ZVRA) estimates and forecasts
Statistics show that Zevra Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Zevra Therapeutics Inc (ZVRA) shares have gone up 31.38% during the last six months, with a year-to-date growth rate less than the industry average at -21.54% against 20.00. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -5.00% this quarter and then jump 20.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -2.20% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 5.34M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 13.66M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.9M and 13.22M respectively. In this case, analysts expect current quarter sales to grow by 84.50% and then jump by 3.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 51.89%. While earnings are projected to return -15.90% in 2024.
ZVRA Dividends
Zevra Therapeutics Inc is due to release its next quarterly earnings in October. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
